Eledon Pharmaceuticals

Company snapshot

Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand (also called “CD154”), a well-validated biologica

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Eledon Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  SANGAMO THERAPEUTICS

  TA overlap score 25

• Peer + 0 momentum

  Genzyme Europe

  TA overlap score 24

Recent activity

Latest pipeline, patent, and corporate events for Eledon Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   AT-1501-K209 — Phase 2

2. Jun 8, 2026 Clinical update

   2025P000818 — Phase 1

3. Jun 5, 2026 Clinical update

   Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy — Phase 2

4. Jun 5, 2026 Clinical update

   AT-1501 IV Infusion — Phase 2

5. May 23, 2026 Clinical update

   AT-1501 — Phase 2

View all clinical trial activity →

• What is Eledon Pharmaceuticals?

  Eledon Pharmaceuticals is a pharma organization headquartered in Irvine, USA. It trades on NYSE under ticker ELDN. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Prophylaxis of Renal Allograft Rejection, Amyotrophic Lateral Sclerosis, IgA Nephropathy, Brittle T

• Is Eledon Pharmaceuticals publicly traded?

  Yes. Eledon Pharmaceuticals is listed with ticker ELDN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Eledon Pharmaceuticals develop or market?

  We link 11 drug profile(s) where Eledon Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eledon-pharmaceuticals#company-drugs.

• What are the latest developments for Eledon Pharmaceuticals?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Eledon Pharmaceuticals focus on?

  Eledon Pharmaceuticals focuses on Type 1 Diabetes Mellitus, Prophylaxis of Renal Allograft Rejection, Amyotrophic Lateral Sclerosis based on our analysis of their pipeline programs and drug development activities.